Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Hold" by Analysts

Key Points

• Immunocore Holdings PLC has received a consensus rating of "Hold" from 11 ratings firms, with one sell, four hold, and six buy ratings.
• The company's stock is currently trading at approximately $36.57, with an average 1-year price target set by analysts at $56.89.
• Institutional investors hold 84.5% of Immunocore's shares, with notable increases in holdings from several firms during the second quarter.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has earned a consensus rating of "Hold" from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $56.8889.

IMCR has been the subject of several recent research reports. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 4th. Jefferies Financial Group initiated coverage on Immunocore in a report on Monday, August 25th. They set a "buy" rating and a $48.00 target price on the stock. Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 target price for the company.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. Osaic Holdings Inc. lifted its holdings in Immunocore by 117.4% in the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company's stock valued at $97,000 after acquiring an additional 1,700 shares during the last quarter. Orion Porfolio Solutions LLC increased its position in shares of Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock valued at $752,000 after acquiring an additional 1,031 shares during the last quarter. State of Tennessee Department of Treasury purchased a new position in shares of Immunocore during the 2nd quarter worth approximately $132,000. Oxford Asset Management LLP acquired a new stake in Immunocore in the 2nd quarter valued at approximately $661,000. Finally, Lazard Asset Management LLC acquired a new position in Immunocore during the second quarter worth $2,789,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Stock Up 0.5%

Shares of NASDAQ IMCR opened at $36.57 on Friday. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -91.43 and a beta of 0.77. The company's 50-day simple moving average is $33.95 and its 200-day simple moving average is $31.73. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. Immunocore has a 52-week low of $23.15 and a 52-week high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm had revenue of $130.65 million for the quarter, compared to analyst estimates of $122.96 million. During the same period last year, the company posted ($0.23) EPS. Immunocore's quarterly revenue was up 30.0% compared to the same quarter last year. Equities analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.